|
|
News Breaks | | | | January 3, 2013 | | 19:05 EDT |  | CORT | Corcept Therapeutics upgraded to Overweight from Underweight at Piper Jaffray
Piper Jaffray upgraded Corcept Therapeutics two notches to Overweight from Underweight with a $4 price target after assuming coverage of the stock. Piper believes the company's increased sales efforts may result in prescription traction for its drug Korlym, which is indicated to treat Cushing’s disease. | |
|
News For CORT From The Last 14 Days Check below for free stories on CORT the last two weeks. |
|
|
| May 24, 2013 | | 17:22 EDT |  | CORT | Corcept Therapeutics enters services agreement with Centric Health
Corcept Therapeutics disclosed in a regulatory filing that on May 21, the company entered into a services agreement with Centric Health Resources to provide the exclusive specialty pharmacy and patient services program for the company's drug Korlym, starting early in Q3. Under the terms of the agreement, subject to certain exceptions, Centric will act as the exclusive specialty pharmacy distributor of the product in the United States for the term of the agreement. The initial term of the agreement is a period of three years from the initiation of services under the agreement. | |
|
|
|
|
|
|
